Our Business Model is highly symbiotic. Our plan is to
collaborate with dairies through our Bridge ™ program, which will
support other potential highly profitable opportunities in gamma
globulin distribution and Nutraceutical production.
Whether it is the IgG production as a result of our patented
plasma extraction from the host herd, or the derivation of
Nutraceutical component materials, we strive to make the very most of
every opportunity and will continue to do so.
Business Model 